Oral Anticoagulation; Improving AF and VTE outcomes (2021 Update)
Direct oral anticoagulants (DOACs) are increasingly encountered in pharmacy practice, for use in patients with atrial fibrillation (AF), deep vein thrombosis (DVT), and peripheral artery disease (PAD). As a result, pharmacists are often asked challenging questions regarding the practical management of patients on DOAC therapy. This lesson provides a practical overview to answering these questions, with a focus on:
- The role of DOAC therapy in patients with atrial fibrillation (AF) and deep vein thrombosis (DVT)
- Optimizing DOAC therapy according to key patient characteristics
- The pharmacist’s role in assessing, managing, and monitoring patients on DOAC therapy
This program has received an unrestricted educational grant or in-kind support from BMS-Pfizer Alliance
This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP) for 2.0 CEU.
CCCEP File Number: 1066-2019-2892-I-P
Francis Richard, PharmD, MScPhm, BCMTMS
John Papastergiou, BSc, BSc(Pharm)
Reginald Smith, BSc(Pharm), Pharm.D.
Upon completion of this continuing education program, participants will be better able to:
- Recommend safe, effective, and appropriate use of direct oral anticoagulant (DOAC) therapy in patients with atrial fibrillation (AF), deep vein thrombosis (DVT), and peripheral artery disease.
- Optimize DOAC therapy and dosage for the management of AF or DVT, based on patient characteristics such as renal function, concomitant medications, bleeding risk, age, and weight.
- Describe strategies for managing anticoagulation in patients undergoing a minor or major surgical procedure.
- Counsel patients on the safe and appropriate use of DOAC medications to support best outcomes